CAR T cells against CART19 (Kymriah) received FDA approval in 2017 to use in pediatric relapsed or refractory ALL and CD19 (Yescarta) for adult relapsed or refractory B cell lymphoma [64]. This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.